BioSpace News Archive

AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has completed enrollment of the initial cohort into Part 1 of its ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, reported financial results for the second quarter ended June 30, 2021.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, announced financial results for the second quarter of 2021 and provided a corporate update.

Instil Bio, Inc. today reported its second quarter 2021 financial results and provided a corporate update.

Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the quarter ended June 30, 2021.

HOOKIPA Pharma Inc. today reported financial results and business highlights for the second quarter of 2021.

Virios Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.